Exscientia, the leading AI-driven drug discovery company, is delighted to announce the opening of its new offices in central Oxford, UK, in the UK’s most dynamic life science cluster.
4 December 2017, Oxford and Dundee, UK
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce the opening of its new offices in central Oxford, UK, in the UK’s most dynamic life science cluster.
In response to the Company’s rapid growth over the last 12 months, Exscientia’s new offices, in the heart of Oxford’s St. Giles’ area, will provide international clients and collaborators with excellent access to Company. In addition, its close proximity to leading academic research institutions in Oxford University will enable opportunities for new collaborations to be fostered. This development is in parallel with the planned expansion of Exscientia’s Dundee offices, another of the UK’s leading scientific centres of excellence.
Andrew Hopkins, CEO of Exscientia, said: “Opening an Oxford office allows us to have a home at the centre of UK biotech creativity. This move comes at a key time for Exscientia, having recently announced exciting strategic partnerships with GSK and Sanofi and our first external investment from Evotec. Our new offices have been carefully designed to foster a creative environment for team members. The expansion of Exscientia at Oxford and Dundee is part of our plan to recruit highly talented personnel to drive our mission to improve the way new medicines are discovered by application of artificial intelligence.”
Exscientia recently won the Best Emerging Biotech Company Award at the OBN Annual Awards ceremony in Oxford.
